⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VIR News
Vir Biotechnology, Inc. Common Stock
genOway:Revolucionando la predicción de terapias con anticuerpos en humanos con un modelo de ratón único USA - español USA - Français USA - English Japan - Japanese USA - Deutsch
prnewswire.com
VIR
genOway : révolutionner la prédiction des thérapies à base d'anticorps chez l'humain grâce à un modèle murin unique USA - Français USA - español USA - English Japan - Japanese USA - Deutsch
prnewswire.com
VIR
GILD
genOway: Revolution der Vorhersage von Antikörpertherapien beim Menschen mit einem einzigartigen Mausmodell USA - Deutsch USA - español USA - Français USA - English Japan - Japanese
prnewswire.com
VIR
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
businesswire.com
VIR
Vir Biotechnology Announces Proposed Public Offering of Common Stock
businesswire.com
VIR
Biotech and Big Tech Drive the Morning Narrative
globenewswire.com
VIR
LRMR
META
AMD
Form 8-K
sec.gov
VIR
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
businesswire.com
VIR
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN ® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
businesswire.com
VIR
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
prnewswire.com
VIR